Nicolas Clara, Wang Yujia, Luebke-Wheeler Jennifer, Nyberg Scott L
William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN 55905, USA.
Department of Surgery, Mayo Clinic, Rochester, MN 55905, USA.
Biomedicines. 2016 Jan 6;4(1):2. doi: 10.3390/biomedicines4010002.
Cell therapy is an emerging form of treatment for several liver diseases, but is limited by the availability of donor livers. Stem cells hold promise as an alternative to the use of primary hepatocytes. We performed an exhaustive review of the literature, with a focus on the latest studies involving the use of stem cells for the treatment of liver disease. Stem cells can be harvested from a number of sources, or can be generated from somatic cells to create induced pluripotent stem cells (iPSCs). Different cell lines have been used experimentally to support liver function and treat inherited metabolic disorders, acute liver failure, cirrhosis, liver cancer, and small-for-size liver transplantations. Cell-based therapeutics may involve gene therapy, cell transplantation, bioartificial liver devices, or bioengineered organs. Research in this field is still very active. Stem cell therapy may, in the future, be used as a bridge to either liver transplantation or endogenous liver regeneration, but efficient differentiation and production protocols must be developed and safety must be demonstrated before it can be applied to clinical practice.
细胞疗法是几种肝脏疾病的新兴治疗方式,但受供体肝脏可用性的限制。干细胞有望成为替代原代肝细胞使用的方法。我们对文献进行了详尽的综述,重点关注涉及使用干细胞治疗肝脏疾病的最新研究。干细胞可以从多种来源获取,也可以从体细胞生成以创建诱导多能干细胞(iPSC)。不同的细胞系已被用于实验,以支持肝功能并治疗遗传性代谢紊乱、急性肝衰竭、肝硬化、肝癌和小体积肝移植。基于细胞的治疗方法可能涉及基因治疗、细胞移植、生物人工肝装置或生物工程器官。该领域的研究仍然非常活跃。干细胞疗法未来可能用作肝移植或内源性肝再生的桥梁,但在应用于临床实践之前,必须制定有效的分化和生产方案并证明其安全性。